Maryland is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
NCT05977907
Recruiting
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC
NCT04093167
Recruiting
BR36 will evaluate the potential clinical benefit of tailoring immunotherapy treatment based on ctDNA molecular response in non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: The Sidney Kimmel Comprehensive Cancer Centre, Baltimore, Maryland
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
Recruiting
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help. Objective: To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide. Eligibility: People with NAFLD and healthy volunteers ages 18 and older Design: Participants will be screened with: Medical history Physical exam... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Register for Updates
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes
NCT03087253
Recruiting
Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States. These rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications diabetes, dyslipidemia and hepatic steatosis. Due to these metabolic problems, atherosclerotic vascular disease, recurrent episodes of acute pancreatitis, cirrhosis and other morbidities complicate the lives of th... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: National Institutes of Health, Bethesda, Maryland
Conditions: Lipodystrophy (Genetic or Acquired, Non HIV)
Register for Updates
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
NCT04171492
Recruiting
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/13/2025
Locations: The Johns Hopkins University, Baltimore, Maryland
Conditions: Nodule Solitary Pulmonary, Non-small Cell Carcinoma
Register for Updates
Transnasal Induction of Normothermia for Neurogenic Fever
NCT06038513
Recruiting
The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/12/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Stroke, Ischemic, Stroke Hemorrhagic, Seizures, Metabolic Encephalopathy
Register for Updates
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
02/12/2025
Locations: Belite Study Site, Hagerstown, Maryland
Conditions: Geographic Atrophy
Register for Updates
SMART-ER: Symptom Monitoring With Patient-reported Outcomes
NCT05560685
Recruiting
The key hypothesis for this study is that collection of the PRO surveys via the Outcomes4Me app is feasible, as measured by survey completion rates. In addition to informing feasibility, this study will provide information about symptom trajectories, symptom management interventions, and early endocrine therapy adherence and persistence. Patients with risk factors for adjuvant endocrine therapy non-adherence or early discontinuation will complete patient-reported outcome (PRO) surveys via smart... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Breast Cancer
Register for Updates
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT03439735
Recruiting
The goal of this research study is to determine if the investigators can predict which participants will respond to endocrine therapy and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor for metastatic breast cancer and which participants will not. Investigators will use information from the tumor tissue and serial blood samples. Investigators hope that a deeper understanding of which participants will respond to this combination and how resistance emerges will allow the investigators to be... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/12/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Breast Cancer
Register for Updates
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
NCT06639958
Recruiting
This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a sp... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
02/11/2025
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Register for Updates
MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD)
NCT06367608
Recruiting
The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating task specific focal hand dystonias (TSFD). TSFD is a type of dystonia that affects hand movements during specific tasks such as writing, playing instruments or typing, often causing involuntarily movements or cramping.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
02/11/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Task-Specific Focal Dystonia
Register for Updates
Transcutaneous Spinal Cord Stimulation in Children with Incomplete Spinal Cord Injury
NCT06242873
Recruiting
Aim 1: Determine the safety and feasibility of administration of TSCS to children in a clinical setting. Participants will be randomly assigned to experimental (TSCS) or control (sham stimulation) groups. Both groups will receive eight-weeks of individualized gait training. We will measure adverse events, including pain and skin irritation, to determine safety as the primary outcome. Hypothesis 1: Administration of TSCS to children in a clinical setting will be safe based on similar safety outco... Read More
Gender:
ALL
Ages:
Between 3 years and 16 years
Trial Updated:
02/11/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Spinal Cord Injuries
Register for Updates